Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

  title={Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials},
  author={D. Bates},
  pages={S14 - S25}
  • D. Bates
  • Published 2011
  • Medicine
  • Neurology
  • Intervention with interferon-β (IFNβ) therapy counters early inflammatory damage to myelin and protects axons; such therapy might demonstrate greater efficacy earlier in the disease course compared with later when permanent damage has already occurred. Clinical trials conducted in patients with clinically isolated syndrome (CIS) show clinical benefits of early treatment of multiple sclerosis (MS), as evidenced by delayed conversion to clinically definite multiple sclerosis and reduced… CONTINUE READING
    85 Citations

    Paper Mentions

    Interventional Clinical Trial
    Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via… Expand
    ConditionsAutoimmune, Multiple Sclerosis
    InterventionDevice, Procedure
    Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    • 13
    • Highly Influenced
    Cladribine in multiple sclerosis: pitfalls in a new treatment landscape
    • F. Paul
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2013
    • 4
    Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
    • 30
    Multiple sclerosis: effect of beta interferon treatment on survival.
    • 10
    • PDF
    Focal segmental glomerulosclerosis secondary to subcutaneous interferon β-1a treatment in a patient with multiple sclerosis.
    • 3
    • Highly Influenced


    Why treat early multiple sclerosis patients?
    • G. Comi
    • Medicine
    • Current opinion in neurology
    • 2000
    • 33
    Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
    • L. Kappos, MS EuropeanStudyGrouponInterferonβ-1binSecondaryProgr
    • Medicine
    • The Lancet
    • 1998
    • 764